European Journal of Medicinal Chemistry (2021)
Update date:2022-08-16
Topics:
Moir, Michael
Lane, Samuel
Montgomery, Andrew P.
Hibbs, David
Connor, Mark
Kassiou, Michael
The development of selective CB2 receptor agonists is a promising therapeutic approach for the treatment of inflammatory diseases, without CB1 receptor mediated psychoactive side effects. Preliminary structure-activity relationship studies on pyrazoylidene benzamide agonists revealed the -ylidene benzamide moiety was crucial for functional activity at the CB2 receptor. A small library of compounds with varying linkage moieties between the pyrazole and substituted phenyl group has culminated in the discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine agonist 19 (CB2R EC50 = 19 nM, CB1R EC50 > 10 μM). Docking studies have revealed key structural features of the linkage group that are important for potent functional activity.
View MoreAnhui Gusheng Import&Export CO.,LTD
Contact:86-551-63662296
Address:Jinzhai Road NO.162 ,hefei, china
Contact:+1-416-493-6870
Address:Toronto, Canada
Contact:+86-29-88710656
Address:South Tai bai Road, High Tech Development Zone, Xi'an China
Anhui Gusheng Import&Export CO.,LTD
Contact:86-551-63662296
Address:Jinzhai Road NO.162 ,hefei, china
Winchem Industrial Co. Ltd.(expird)
Contact:86-574-83851061 86-574-87083208
Address:Room 905, No.3 Building,East Business Center, 456 Xingning Road, Ningbo City,China
Doi:10.1016/0039-128X(72)90021-9
(1972)Doi:10.1021/jacs.1c02622
(2021)Doi:10.1007/s00706-002-0505-8
(2003)Doi:10.1107/S0108270103001069
(2003)Doi:10.1016/j.tet.2019.130512
(2019)Doi:10.1177/1747519819868202
(2019)